Center Laboratories, Inc. (4123.TWO)
TWD 35.35
(-2.62%)
TWD 35.35
(-2.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -79.26 Million TWD | -160.08% |
| 2022 | 131.93 Million TWD | -87.37% |
| 2021 | 1.04 Billion TWD | 257.79% |
| 2020 | 291.97 Million TWD | 339.79% |
| 2019 | -121.76 Million TWD | -109.45% |
| 2018 | 1.28 Billion TWD | 45.03% |
| 2017 | 888.03 Million TWD | 106.7% |
| 2016 | 429.63 Million TWD | 1020.22% |
| 2015 | -46.68 Million TWD | 32.83% |
| 2014 | -69.5 Million TWD | -74.4% |
| 2013 | -39.85 Million TWD | 1.85% |
| 2012 | -40.6 Million TWD | -1021.44% |
| 2011 | 4.4 Million TWD | 119.73% |
| 2010 | -22.33 Million TWD | -715.09% |
| 2009 | 3.63 Million TWD | -88.75% |
| 2008 | 32.26 Million TWD | -28.07% |
| 2007 | 44.85 Million TWD | 31.97% |
| 2006 | 33.98 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 56.16 Million TWD | 33.65% |
| 2024 Q1 | 42.02 Million TWD | 1319.5% |
| 2023 Q2 | -161.76 Million TWD | -242.77% |
| 2023 Q4 | -3.44 Million TWD | 96.57% |
| 2023 Q3 | -100.55 Million TWD | 37.84% |
| 2023 FY | -79.26 Million TWD | -160.08% |
| 2023 Q1 | 113.3 Million TWD | 138.42% |
| 2022 Q3 | 47.41 Million TWD | -75.61% |
| 2022 Q2 | 194.38 Million TWD | 5.04% |
| 2022 Q4 | -294.91 Million TWD | -722.01% |
| 2022 FY | 131.93 Million TWD | -87.37% |
| 2022 Q1 | 185.05 Million TWD | 122.51% |
| 2021 FY | 1.04 Billion TWD | 257.79% |
| 2021 Q3 | 132.97 Million TWD | 185.59% |
| 2021 Q4 | -821.99 Million TWD | -718.14% |
| 2021 Q2 | -155.36 Million TWD | 51.36% |
| 2021 Q1 | -319.4 Million TWD | -151.08% |
| 2020 Q4 | -127.21 Million TWD | 58.3% |
| 2020 Q3 | -305.07 Million TWD | -768.08% |
| 2020 Q2 | -35.14 Million TWD | -554.69% |
| 2020 FY | 291.97 Million TWD | 339.79% |
| 2020 Q1 | -5.36 Million TWD | 91.98% |
| 2019 FY | -121.76 Million TWD | -109.45% |
| 2019 Q2 | -35.96 Million TWD | -310.28% |
| 2019 Q3 | -3.29 Million TWD | 90.85% |
| 2019 Q4 | -66.91 Million TWD | -1933.3% |
| 2019 Q1 | 17.1 Million TWD | 488.66% |
| 2018 Q2 | 586.71 Million TWD | 60.18% |
| 2018 FY | 1.28 Billion TWD | 45.03% |
| 2018 Q4 | -4.4 Million TWD | -101.3% |
| 2018 Q3 | 339.28 Million TWD | -42.17% |
| 2018 Q1 | 366.29 Million TWD | 57.65% |
| 2017 Q4 | 232.34 Million TWD | 72.5% |
| 2017 FY | 888.03 Million TWD | 106.7% |
| 2017 Q2 | 318.25 Million TWD | 56.98% |
| 2017 Q3 | 134.69 Million TWD | -57.68% |
| 2017 Q1 | 202.73 Million TWD | 149.83% |
| 2016 Q4 | 81.15 Million TWD | 581.88% |
| 2016 FY | 429.63 Million TWD | 1020.22% |
| 2016 Q3 | 11.9 Million TWD | -89.96% |
| 2016 Q2 | 118.58 Million TWD | -45.6% |
| 2016 Q1 | 217.99 Million TWD | 558.76% |
| 2015 FY | -46.68 Million TWD | 32.83% |
| 2015 Q1 | -11.4 Million TWD | 76.9% |
| 2015 Q3 | -38.92 Million TWD | -32.18% |
| 2015 Q4 | 33.09 Million TWD | 185.02% |
| 2015 Q2 | -29.44 Million TWD | -158.1% |
| 2014 Q3 | 1.3 Million TWD | 106.87% |
| 2014 FY | -69.5 Million TWD | -74.4% |
| 2014 Q4 | -49.38 Million TWD | -3884.6% |
| 2014 Q2 | -18.98 Million TWD | -678.31% |
| 2014 Q1 | -2.43 Million TWD | -87.47% |
| 2013 Q3 | -20.64 Million TWD | -8.37% |
| 2013 FY | -39.85 Million TWD | 1.85% |
| 2013 Q1 | 1.15 Million TWD | 107.31% |
| 2013 Q2 | -19.05 Million TWD | -1756.96% |
| 2013 Q4 | -1.3 Million TWD | 93.7% |
| 2012 Q4 | -15.73 Million TWD | 10.64% |
| 2012 FY | -40.6 Million TWD | -1021.44% |
| 2012 Q1 | 9.73 Million TWD | 155.31% |
| 2012 Q2 | -17.23 Million TWD | -277.03% |
| 2012 Q3 | -17.6 Million TWD | -2.14% |
| 2011 Q3 | -8.87 Million TWD | 22.04% |
| 2011 Q4 | 3.81 Million TWD | 142.95% |
| 2011 FY | 4.4 Million TWD | 119.73% |
| 2011 Q1 | 20.86 Million TWD | 664.24% |
| 2011 Q2 | -11.38 Million TWD | -154.59% |
| 2010 Q1 | -971 Thousand TWD | 0.0% |
| 2010 Q2 | -4.8 Million TWD | -394.54% |
| 2010 Q4 | -3.69 Million TWD | 71.26% |
| 2010 FY | -22.33 Million TWD | -715.09% |
| 2010 Q3 | -12.86 Million TWD | -167.89% |
| 2009 FY | 3.63 Million TWD | -88.75% |
| 2008 FY | 32.26 Million TWD | -28.07% |
| 2007 FY | 44.85 Million TWD | 31.97% |
| 2006 FY | 33.98 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Allied Biotech Corporation | 88.71 Million TWD | 189.349% |
| GeneFerm Biotechnology Co., Ltd. | 153.56 Million TWD | 151.617% |
| Easywell Biomedicals, Inc. | -162.73 Million TWD | 51.293% |
| TTY Biopharm Company Limited | 1.37 Billion TWD | 105.776% |
| Synmosa Biopharma Corporation | 614.74 Million TWD | 112.894% |
| Orient EuroPharma Co., Ltd. | 84.55 Million TWD | 193.745% |
| Tien Liang BioTech Co., Ltd. | 20.43 Million TWD | 487.869% |
| Orient Pharma Co., Ltd. | 27.75 Million TWD | 385.609% |
| InnoPharmax Inc. | -64.83 Million TWD | -22.249% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 105.57 Million TWD | 175.082% |
| Excelsior Biopharma Inc. | -81.12 Million TWD | 2.296% |
| DV Biomed Co., Ltd. | 173.54 Million TWD | 145.673% |
| Foresee Pharmaceuticals Co., Ltd. | -1 Billion TWD | 92.133% |
| Handa Pharmaceuticals, Inc. | 695.79 Million TWD | 111.392% |
| UniPharma Co., Ltd. | -27.3 Million TWD | -190.295% |
| Anxo Pharmaceutical Co., Ltd. | 53.15 Million TWD | 249.126% |
| Alar Pharmaceuticals Inc. | 385.52 Million TWD | 120.56% |
| Winston Medical Supply Co., Ltd. | 196.1 Million TWD | 140.42% |
| Mercury Biopharmaceutical Corporation | -45.69 Million TWD | -73.484% |
| Bioray Biotech Co., Ltd | -19.33 Million TWD | -310.041% |
| TSH Biopharm Corporation Limited | 63.63 Million TWD | 224.572% |